[{"orgOrder":0,"company":"Evotec","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"Induced pluripotent stem cells","moa":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Evotec","amount2":0.01,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"","sponsorNew":"Evotec \/ Bristol-Myers Squibb","highestDevelopmentStatusID":"1","companyTruncated":"Evotec \/ Bristol-Myers Squibb"},{"orgOrder":0,"company":"Evotec","sponsor":"OncoResponse","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"OR2805","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Evotec","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Evotec \/ OncoResponse","highestDevelopmentStatusID":"7","companyTruncated":"Evotec \/ OncoResponse"},{"orgOrder":0,"company":"Evotec","sponsor":"Ildong Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"GERMANY","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"IDG-16177","moa":"","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Evotec","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"Evotec \/ Ildong","highestDevelopmentStatusID":"1","companyTruncated":"Evotec \/ Ildong"},{"orgOrder":0,"company":"Rigenerand","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"RR001","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Rigenerand","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Rigenerand \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Rigenerand \/ Not Applicable"},{"orgOrder":0,"company":"Evotec","sponsor":"HitGen","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Evotec","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Evotec \/ Evotec SE","highestDevelopmentStatusID":"2","companyTruncated":"Evotec \/ Evotec SE"},{"orgOrder":0,"company":"Evotec","sponsor":"Secarna Pharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2020","type":"Partnership","leadProduct":"Antisense oligonucleotide therapy","moa":"","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Evotec","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Evotec \/ Evotec","highestDevelopmentStatusID":"3","companyTruncated":"Evotec \/ Evotec"},{"orgOrder":0,"company":"Evotec","sponsor":"Centogene","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Expanded Collaboration","leadProduct":"Induced pluripotent stem cell","moa":"","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Evotec","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Evotec \/ CENTOGENE","highestDevelopmentStatusID":"2","companyTruncated":"Evotec \/ CENTOGENE"},{"orgOrder":0,"company":"Evotec","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2020","type":"Funding","leadProduct":"Anti-SARS-CoV-2 antibody","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Evotec","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Evotec \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"2","companyTruncated":"Evotec \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Evotec","sponsor":"Evotec","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"GERMANY","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"Exosomes","moa":"","graph1":"Immunology","graph2":"Undisclosed","graph3":"Evotec","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Evotec \/ Evotec","highestDevelopmentStatusID":"1","companyTruncated":"Evotec \/ Evotec"},{"orgOrder":0,"company":"Evotec","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"EVT894","moa":"Chikungunya viral protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Evotec","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"intravenous infusion","sponsorNew":"Evotec \/ National Institute Health","highestDevelopmentStatusID":"6","companyTruncated":"Evotec \/ National Institute Health"},{"orgOrder":0,"company":"Evotec","sponsor":"Chinook Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Nephrology","graph2":"Discovery Platform","graph3":"Evotec","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"","sponsorNew":"Evotec \/ Chinook Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Evotec \/ Chinook Therapeutics"},{"orgOrder":0,"company":"Evotec","sponsor":"Exscientia","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Undisclosed","moa":"A2AR","graph1":"Oncology","graph2":"Phase I","graph3":"Evotec","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Evotec \/ Evotec","highestDevelopmentStatusID":"6","companyTruncated":"Evotec \/ Evotec"},{"orgOrder":0,"company":"Evotec","sponsor":"Kazia Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"EVT801","moa":"VEGFR 3","graph1":"Oncology","graph2":"Preclinical","graph3":"Evotec","amount2":0.37,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.37,"dosageForm":"Oral","sponsorNew":"Evotec \/ Kazia Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Evotec \/ Kazia Therapeutics"},{"orgOrder":0,"company":"Evotec","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Protein degradation","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Evotec","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Evotec \/ Bristol Myers Squibb","highestDevelopmentStatusID":"3","companyTruncated":"Evotec \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Evotec","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"RNA","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Evotec","amount2":0.16,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.16,"dosageForm":"","sponsorNew":"Evotec \/ Takeda","highestDevelopmentStatusID":"3","companyTruncated":"Evotec \/ Takeda"},{"orgOrder":0,"company":"Evotec","sponsor":"Pasithea Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2021","type":"Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Discovery","graph3":"Evotec","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"Evotec \/ Pasithea Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Evotec \/ Pasithea Therapeutics"},{"orgOrder":0,"company":"Evotec","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Expanded Collaboration","leadProduct":"iPSC-based Cell Therapy","moa":"","graph1":"Neurology","graph2":"Discovery","graph3":"Evotec","amount2":0.28000000000000003,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0.28000000000000003,"dosageForm":"","sponsorNew":"Evotec \/ Evotec","highestDevelopmentStatusID":"2","companyTruncated":"Evotec \/ Evotec"},{"orgOrder":0,"company":"Evotec","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"EVT8683","moa":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Evotec","amount2":0.27000000000000002,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Evotec \/ Bristol Myers Squibb","highestDevelopmentStatusID":"5","companyTruncated":"Evotec \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Evotec","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"EVT8683","moa":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Evotec","amount2":0.040000000000000001,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Evotec \/ Bristol Myers Squibb","highestDevelopmentStatusID":"5","companyTruncated":"Evotec \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Evotec","sponsor":"Kazia Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"EVT801","moa":"VEGFR 3","graph1":"Oncology","graph2":"Phase I","graph3":"Evotec","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Evotec \/ Evotec","highestDevelopmentStatusID":"6","companyTruncated":"Evotec \/ Evotec"},{"orgOrder":0,"company":"Evotec","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"","graph1":"Ophthalmology","graph2":"Discovery Platform","graph3":"Evotec","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"","sponsorNew":"Evotec \/ Boehringer Ingelheim","highestDevelopmentStatusID":"3","companyTruncated":"Evotec \/ Boehringer Ingelheim"},{"orgOrder":0,"company":"Evotec","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Undisclosed","year":"2022","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"Protein","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Evotec","amount2":0.28999999999999998,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0.28999999999999998,"dosageForm":"","sponsorNew":"Evotec \/ Bristol Myers Squibb","highestDevelopmentStatusID":"3","companyTruncated":"Evotec \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Evotec","sponsor":"Celmatix","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Undisclosed","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Preclinical","graph3":"Evotec","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"","sponsorNew":"Evotec \/ Evotec","highestDevelopmentStatusID":"4","companyTruncated":"Evotec \/ Evotec"},{"orgOrder":0,"company":"Evotec","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Eliapixant","moa":"P2X3 receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Evotec","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Evotec \/ Evotec","highestDevelopmentStatusID":"8","companyTruncated":"Evotec \/ Evotec"},{"orgOrder":0,"company":"Evotec","sponsor":"Chinook Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"BION-1301","moa":"BCMA receptor","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"Evotec","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Evotec \/ Evotec","highestDevelopmentStatusID":"7","companyTruncated":"Evotec \/ Evotec"},{"orgOrder":0,"company":"Evotec","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Evotec","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Evotec \/ Janssen","highestDevelopmentStatusID":"3","companyTruncated":"Evotec \/ Janssen"},{"orgOrder":0,"company":"Evotec","sponsor":"Exscientia","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"EXS-21546","moa":"A2AR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Evotec","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Evotec \/ Evotec","highestDevelopmentStatusID":"7","companyTruncated":"Evotec \/ Evotec"},{"orgOrder":0,"company":"Evotec","sponsor":"Sernova Corp.","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Partnership","leadProduct":"iPSC-based Beta Cell Replacement Therapy","moa":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Evotec","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Evotec \/ Sernova Corp.","highestDevelopmentStatusID":"4","companyTruncated":"Evotec \/ Sernova Corp."},{"orgOrder":0,"company":"Evotec","sponsor":"Alpine Immune Sciences","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2022","type":"Expanded Collaboration","leadProduct":"ALPN-303","moa":"BAFF\/APRIL","graph1":"Immunology","graph2":"Phase I","graph3":"Evotec","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Evotec \/ Alpine Immune Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Evotec \/ Alpine Immune Sciences"},{"orgOrder":0,"company":"Evotec","sponsor":"Sernova","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Financing","leadProduct":"Human Donor Islets Cell","moa":"","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Evotec","amount2":0.27000000000000002,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","amount2New":0.27000000000000002,"dosageForm":"Implant","sponsorNew":"Evotec \/ Evotec","highestDevelopmentStatusID":"7","companyTruncated":"Evotec \/ Evotec"},{"orgOrder":0,"company":"Evotec","sponsor":"Kazia Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"EVT801","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Evotec","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Evotec \/ Evotec","highestDevelopmentStatusID":"6","companyTruncated":"Evotec \/ Evotec"},{"orgOrder":0,"company":"Evotec","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"EVT8683","moa":"","graph1":"Neurology","graph2":"Discovery","graph3":"Evotec","amount2":0.029999999999999999,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Evotec \/ Bristol Myers Squibb","highestDevelopmentStatusID":"2","companyTruncated":"Evotec \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Evotec","sponsor":"Sernova","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"Human Donor Islets Cell","moa":"","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Evotec","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Evotec \/ Evotec","highestDevelopmentStatusID":"7","companyTruncated":"Evotec \/ Evotec"},{"orgOrder":0,"company":"Evotec","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Evotec","amount2":0.34999999999999998,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.34999999999999998,"dosageForm":"","sponsorNew":"Evotec \/ Janssen Pharmaceutical","highestDevelopmentStatusID":"2","companyTruncated":"Evotec \/ Janssen Pharmaceutical"},{"orgOrder":0,"company":"Evotec","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Nephrology","graph2":"Discovery","graph3":"Evotec","amount2":1,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Nephrology","amount2New":1,"dosageForm":"Oral","sponsorNew":"Evotec \/ Eli Lilly","highestDevelopmentStatusID":"2","companyTruncated":"Evotec \/ Eli Lilly"},{"orgOrder":0,"company":"Evotec","sponsor":"Related Sciences","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"","productType":"Undisclosed","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Evotec","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Evotec \/ Related Sciences","highestDevelopmentStatusID":"3","companyTruncated":"Evotec \/ Related Sciences"},{"orgOrder":0,"company":"Evotec","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Evotec","amount2":5.2000000000000002,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":5.2000000000000002,"dosageForm":"","sponsorNew":"Evotec \/ Bristol Myers Squibb","highestDevelopmentStatusID":"3","companyTruncated":"Evotec \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Evotec","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Undisclosed","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Evotec","amount2":0.01,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"","sponsorNew":"Evotec \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"2","companyTruncated":"Evotec \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Evotec","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Evotec","amount2":5.2000000000000002,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":5.2000000000000002,"dosageForm":"","sponsorNew":"Evotec \/ Bristol Myers Squibb","highestDevelopmentStatusID":"3","companyTruncated":"Evotec \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Evotec","sponsor":"Open Philanthropy","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Evotec","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Evotec \/ Open Philanthropy","highestDevelopmentStatusID":"2","companyTruncated":"Evotec \/ Open Philanthropy"},{"orgOrder":0,"company":"Evotec","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"BAY401016","moa":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Evotec","amount2":0.34999999999999998,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0.34999999999999998,"dosageForm":"","sponsorNew":"Evotec \/ Bayer AG","highestDevelopmentStatusID":"6","companyTruncated":"Evotec \/ Bayer AG"},{"orgOrder":0,"company":"Evotec","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2023","type":"Agreement","leadProduct":"Monoclonal Antibody","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Evotec","amount2":0.070000000000000007,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"Evotec \/ U.S. Department of Defense","highestDevelopmentStatusID":"2","companyTruncated":"Evotec \/ U.S. Department of Defense"},{"orgOrder":0,"company":"Evotec","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Undisclosed","year":"2023","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Neurology","graph2":"Discovery","graph3":"Evotec","amount2":4,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":4,"dosageForm":"","sponsorNew":"Evotec \/ Bristol Myers Squibb","highestDevelopmentStatusID":"2","companyTruncated":"Evotec \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Evotec","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery Platform","graph3":"Evotec","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Evotec \/ Evotec","highestDevelopmentStatusID":"3","companyTruncated":"Evotec \/ Evotec"},{"orgOrder":0,"company":"Evotec","sponsor":"IAMA Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Agreement","leadProduct":"IAMA-6","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Evotec","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Evotec \/ Evotec","highestDevelopmentStatusID":"4","companyTruncated":"Evotec \/ Evotec"},{"orgOrder":0,"company":"Evotec","sponsor":"Glycotope","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Evotec","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Evotec \/ Evotec","highestDevelopmentStatusID":"2","companyTruncated":"Evotec \/ Evotec"},{"orgOrder":0,"company":"Evotec","sponsor":"Variant Bio","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Discovery","graph3":"Evotec","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"","sponsorNew":"Evotec \/ Variant Bio","highestDevelopmentStatusID":"2","companyTruncated":"Evotec \/ Variant Bio"},{"orgOrder":0,"company":"Evotec","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Collaboration","leadProduct":"iPSC-based Therapy","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery","graph3":"Evotec","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Evotec \/ Bayer AG","highestDevelopmentStatusID":"2","companyTruncated":"Evotec \/ Bayer AG"},{"orgOrder":0,"company":"Evotec","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Evotec","amount2":4,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":4,"dosageForm":"","sponsorNew":"Evotec \/ Bristol Myers Squibb","highestDevelopmentStatusID":"4","companyTruncated":"Evotec \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Evotec","sponsor":"Inserm","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Evotec","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Evotec \/ Inserm","highestDevelopmentStatusID":"4","companyTruncated":"Evotec \/ Inserm"},{"orgOrder":0,"company":"Evotec","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Evotec","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Evotec \/ Pfizer Inc","highestDevelopmentStatusID":"14","companyTruncated":"Evotec \/ Pfizer Inc"},{"orgOrder":0,"company":"Evotec","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"BMS-986419","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Evotec","amount2":4,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Evotec \/ Bristol Myers Squibb","highestDevelopmentStatusID":"14","companyTruncated":"Evotec \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Evotec","sponsor":"X-Chem","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Evotec","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Evotec \/ Evotec","highestDevelopmentStatusID":"14","companyTruncated":"Evotec \/ Evotec"}]

Find Clinical Drug Pipeline Developments & Deals by Evotec

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : The collaboration aims to accelerate early-stage drug discovery by using X-Chem’s DEL technology which streamlines hit finding by simultaneously screening up to billions of DNA-tagged compounds.

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          September 05, 2024

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Technology

                          Highest Development Status : Discovery Platform

                          Recipient : X-Chem

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          02

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : A target-based programme progresses into late preclinical development, contributing to pipeline of discovery to clinical-stage programmes in neurodegeneration that the partnership has generated.

                          Brand Name : EVT8683

                          Molecule Type : Small molecule

                          Upfront Cash : $50.0 million

                          August 08, 2024

                          Lead Product(s) : BMS-986419

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I

                          Sponsor : Bristol Myers Squibb

                          Deal Size : $4,000.0 million

                          Deal Type : Collaboration

                          blank

                          03

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : Evotec will collaborate with Pfizer to discover, and research potential new first-in-class therapeutic approaches for the treatment of metabolic and infectious diseases.

                          Brand Name : Undisclosed

                          Molecule Type : Undisclosed

                          Upfront Cash : Undisclosed

                          July 10, 2024

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Discovery

                          Sponsor : Pfizer Inc

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          04

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : A target-based programme progresses into late preclinical development, contributing to pipeline of discovery to clinical-stage programmes in neurodegeneration that the partnership has generated.

                          Brand Name : Undisclosed

                          Molecule Type : Undisclosed

                          Upfront Cash : $50.0 million

                          June 13, 2024

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Neurology

                          Highest Development Status : Preclinical

                          Sponsor : Bristol Myers Squibb

                          Deal Size : $4,000.0 million

                          Deal Type : Collaboration

                          blank

                          05

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : The collaboration aims to identify novel therapeutic targets and diagnostic and prognostic markers in obesity and metabolic diseases by leveraging PanOmics technologies of Evotech.

                          Brand Name : Undisclosed

                          Molecule Type : Undisclosed

                          Upfront Cash : Undisclosed

                          May 30, 2024

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Nutrition and Weight Loss

                          Highest Development Status : Discovery

                          Sponsor : Inserm

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          06

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : The collaboration aims to identify & validate novel targets building a portfolio of precision cardiology therapeutics by leveraging Evotec's disease modeling with human induced pluripotent stem cells.

                          Brand Name : Undisclosed

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          April 30, 2024

                          Lead Product(s) : iPSC-based Therapy

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Discovery

                          Sponsor : Bayer AG

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          07

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : The strategic partnership leverages Variant Bio's cutting-edge genomic discovery capabilities and VB-Inference platform to identify a best-in-class small molecule for diseases caused by fibrosis.

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          April 18, 2024

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                          Highest Development Status : Discovery

                          Sponsor : Variant Bio

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          08

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : The agreement aims to combine Glycotope’s antibodies with Evotec’s immune cell engager platform for the development of next generation immune cell engaging bispecifics by Evotec.

                          Brand Name : Undisclosed

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          December 11, 2023

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Discovery

                          Recipient : Glycotope

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          09

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : Evotec will provide IAMA with preclinical and clinical services to support the anticipated Phase 1 clinical trial to investigate IAMA's lead program IAMA-6, a small molecule therapeutic targeting NKCC1 for the treatment of autism and epilepsy.

                          Brand Name : IAMA-6

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          October 02, 2023

                          Lead Product(s) : IAMA-6

                          Therapeutic Area : Neurology

                          Highest Development Status : Preclinical

                          Recipient : IAMA Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          10

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : The collaboration aims to accelerate the translation of academic ideas to therapeutic product candidates in the cardiometabolic space through LAB eN² that combines Evotec's multimodality drug discovery and preclinical development capabilities.

                          Brand Name : Undisclosed

                          Molecule Type : Undisclosed

                          Upfront Cash : Undisclosed

                          September 26, 2023

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Discovery Platform

                          Recipient : Novo Nordisk

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank